Association of Hepatitis-B virus infection status with survival and treatment response in non-small cell lung cancer patients on anti‐pd‐1/pd-l1 therapy
AIM: HBV reactivation is a significant risk for cancer patients undergoing immunosuppressive or chemotherapy. However, since these patients are often excluded from immunotherapy trials, the safety of anti-PD-1 and anti-PD-L1 therapies in this context remains unclear. Recent advances in cancer treatm...
Saved in:
| Main Authors: | Eda Alp, Goncagul Akdag Topal, DENİZ IŞIK, Nedim Turan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716524004259 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of a Mammalian Cell Line for Stable Production of Anti-PD-1
by: Erika Csató-Kovács, et al.
Published: (2024-10-01) -
The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study
by: Baoyue Pan, et al.
Published: (2025-06-01) -
Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy
by: Dweeti Nayak, et al.
Published: (2025-08-01) -
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
by: David Dora, et al.
Published: (2023-12-01) -
T-cell invigoration to cell-free DNA ratio associated with anti-PD-1 response in gastric or gastro-esophageal junction adenocarcinoma: VOYAGER trial
by: A. Makiyama, et al.
Published: (2025-06-01)